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Introduction
Intravenous leiomyomatosis (IVL) is an uncommon variant 
of benign leiomyomas. Unlike classical uterine leiomyomas 
which are firm, well circumscribed, and localized to the pel-
vic cavity, IVL clinically manifests as a fragile and malleable 
leiomyoma that extends through adjacent venous structures 
in a worm-like fashion [1]. In rare cases, IVL paradoxically 
manifests as a benign leiomyoma infiltrating into the right 
heart chamber and the lungs [2]. IVL is difficult to diagnose 
preoperatively due to the wide range of clinical manifesta-
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tions, and thus histological differential diagnosis is often 
required to differentiate IVL from other diagnoses that are 
categorized together with benign metastasizing leiomyoma 
(BML) and diffuse peritoneal leiomyomatosis (DPL) under 
smooth muscle tumors with unusual growth pattern [3]. 
Despite their extrauterine manifestation, these aberrant of 
benign leiomyomas are pathologically distinguished from 
leiomyosarcoma in that sarcoma is marked by mitotic index 
of greater than 10, high grade cellular atypia, and presence 
of coagulative tumor cell necrosis [4]. Pathologically, in IVL, 
benign appearing smooth muscle cells that are found within 
uterus venous structures show low mitotic activity and stain 
positively for actin and desmin [5]. 
BML is characterized by monoclonal proliferation and he-
matogenous spread of smooth muscle cells from uterine 
leiomyoma to distant locations, most commonly the lungs 
[6,7]. Furthermore, recent investigations involving compara-
tive genetic hybridization, clonal number, and copy variance 
showed that IVL and BML share the same cytogenetic origin 
[8]. Histologically, leiomyomas in BML demonstrate strong 
and diffuse positivity for smooth muscle actin (SMA), estro-
gen receptor (ER), and progesterone receptor (PR). For both 
IVL and BML, treatment of choice is total resection of the le-
sion involved, if possible. Currently there is no consensus on 
the choice of adjuvant; however, hormonal treatment with 
progestin, tamoxifen, or a gonadotropin agonist has been 
suggested [9].
In this study, we encapsulated a single center experience 
with 10 cases of IVL and 2 cases of BML. All the cases were 
pathologically confirmed after primary surgery and followed 
up for adjuvant therapy and disease recurrence. The goal 
of our study was to review the recent literature in this field 
and present a series of representative cases in terms of their 
preoperative clinical characteristics, operative outcomes, and 
follow up.
Materials and methods 
1. Patient enrollment and data collection 
We retrospectively reviewed patients diagnosed with IVL 
and BML at the Severance Hospital from November 2005 
to March 2017. Institutional Review Board approval was 
obtained. Electronic medical records were reviewed to ob-
tain initial symptoms; findings from pre-operative imaging 
and laboratory studies; operative findings and pathologic 
features; and follow up information. The primary imaging 
modality was trans-vaginal ultrasound with the exception 
of patients with extensive disease, which necessitated other 
modalities such as pelvic magnetic resonance imaging (MRI), 
trans-thoracic echocardiography, abdomen or chest com-
puted tomography (CT), and positron emission tomography 
(PET).
2.  Classification of symptoms and clinical 
manifestation
Based on evaluation prior to primary operation, patients were 
divided into early stage versus late stage group, following 
the staging system suggested by Ma et al. [10]. Patients with 
tumors which have penetrated the uterine venous wall, but 
were confined to the pelvic cavity, were categorized as stage 
I. Patients with tumors which have grown into ovarian vein 
or iliac vein and with extension into abdominal cavity at the 
level below the renal vein were categorized as stage II. Stage 
III included patients with extension of tumor through infe-
rior vena cava (IVC) into the right atrium. When tumor pro-
gressed to involve the lung parenchyma, patients were classi-
fied as stage IV. Initial symptom was classified based on each 
patient’s chief complaint, which included abnormal vaginal 
bleeding, abdominal pain, mass palpation or abdominal dis-
tension, and cardio-pulmonary symptoms such as chest pain 
and syncope.
3. Statistical analysis
The SPSS statistical software package (SPSS version 23.0; IBM, 
Chicago, IL, USA) was used for the statistical analysis. The 
nonparametric (Mann-Whitney U or χ2 tests) and the para-
metric (Student’s t -test) tests were used as appropriate for 
comparisons. A significance level of 0.05 (P<0.05) was used 
in all tests.
Results
1. Patient characteristics 
Out of 35 patients diagnosed with leiomyomatosis, 8 pa-
tients with DPL and 15 patients with lymphangioleiomyo-
matosis were excluded (Fig. 1). A total of 12 patients were 
included: 10 patients with IVL and 2 patients with BML. 
All patients were pre-menopausal with median age of 46 
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years, except for 1 patient who was 60 years old at time of 
diagnosis (range, 35–60 years). Patients were parous with 
an average gravida of 4.27. The proportion of those with a 
history of cesarean section and vaginal delivery were similar. 
Most patients had a history of dilation and curettage (D&C) 
procedures (91.7%), whereas only 2 patients had a history 
of laparoscopic myomectomy (16.6%). The blood and se-
rum laboratory values (mean±standard deviation) are listed 
in Table 1. Complete blood count showed hemoglobin levels 
of 11.1±1.72 g/dL, platelet levels of 216±88.7 K/µL, white 
blood cell count of 6,710±3,077 cells/µL. Serum cancer 
antigen (CA) 125 and CA19-9 tumor marker levels were 
16.0±11.5 U/mL and 3.03±1.21 U/mL, respectively. Calcium 
(8.7±0.3 mg/dL) and phosphate (3.48±0.53 mg/dL) levels 
were within normal ranges. The calculated neutrophil leu-
kocyte ratio (NLR) was 7.20±8.09 and the platelet leukocyte 
ratio (PLR) was 0.19±0.07.
Initial manifestations and follow up records are summarized 
in Table 2. Of the 12 patients, disease extent was limited to 
the pelvic cavity (stage I) in 4 patients (33.3%), beneath renal 
vein (stage II) in 4 patients (33.3%), into cardiac chamber 
(stage III) in 2 patients (16.7%), and to bilateral lungs (stage 
IV) in 2 patients (16.7%). In total, the most common present-
Fig. 1. Flowchart of patient enrollment in the study. DPL, diffuse 
peritoneal leiomyomatosis; LAM, lymphangioleiomyomatosis; IVL, 
intravenous leiomyomatosis; BML, benign metastasizing leiomyoma.
Leiomyomatosis patients with 
Diagnosis from 2005 to 2017
Total of 35 patients analyzed
Exclusion of 23 patients 
n=8 DPL 
n=15 LAM
Inclusion of 12 patients 
n=10 IVL
n=2 BML
Table 1. Patient characteristics
Patient characteristics No. of patients (n=12) Percentage (%)
Age (yr) 46 (35–60)
BMI (index) 25.4 (17–39)
Laboratory values 
CA125 16.0±11.5
CA19-9  3.03±1.21
Hemoglobin 11.12±1.72
Platelet 216,000±88,700
White blood cell count 6,710±3,077
Neutrophil lymphocyte ratio 7.20±8.09
Platelet lymphocyte ratio 0.19±0.07
Calcium 8.70±0.36
Phosphate 3.48±0.53
Gynecological history
Vaginal delivery   7 58.3
Cesarean section   5 41.6
Intrauterine device usage   3 25.0
Dilation and curettage 11 91.7
Myomectomy   2 16.6
Hysterectomy   0     0.00
Age and body mass index are presented as median (range) and average (range). Laboratory values shown are mean±standard deviation.
BMI, body mass index; CA, cancer antigen.
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ing symptoms were abnormal uterine bleeding (33.3%) and 
pelvic mass (41.7%). For patients with leiomyoma extension 
to cardiac chamber, the initial presenting symptoms included 
chest discomfort and syncope.
To compare the clinical and laboratory values between early 
and late stage IVL, patients in the early stage IVL (stage I) and 
late stage IVL (stages II, III, and IV) groups were stratified ac-
cording to clinical and laboratory values (Table 3). Average 
age, body mass index, and clinical history such as cesarean 
section, vaginal delivery, history of D&C procedures, myomec-
tomy, and history of intrauterine device (IUD) usage were not 
statistically different. Serum creatinine, calcium, phosphate, 
and albumin levels were not statistically different. NLR of late 
stage IVL showed a tendency to be higher than that of early 
stage IVL (10.4 vs. 1.51, P=0.07). PLR of late stage IVL was 
significantly higher than that of early stage IVL (0.23 vs. 0.13, 
P=0.04). 
Median years of follow up were 5 years. Of the 4 patients 
diagnosed with stage I IVL, the recurrence rate was 0% after 
complete resection. In 4 patients diagnosed with stage II IVL, 
50.0% of patients had persistent disease or intra pelvic recur-
rence. Both patients with stage III IVL showed no recurrence in 
both the pelvic and chest cavity. One of the 2 stage IV IVL pa-
tients had persistent disease on follow up. Despite the events 
of recurrence or persistent disease, there was no operative, 
hospital, or long-term mortality for the observed period. 
2. Case series
1) Case 1 (stage I, patient #3) 
A 46-year-old patient was referred for lower abdominal pain. 
On sonography, a conglomeration of multiple intramural leio-
myomas was detected at the posterior wall of the uterus (Fig. 2). 
Further evaluation with MRI revealed a 7.4×10 cm sized lobu-
lated subserosal myoma with an internal hemorrhagic area 
and dilated pelvic and uterine vessels. Uterine sarcoma was 
proposed as less likely on differential diagnosis. The patient 
was scheduled to undergo total abdominal hysterectomy (TAH) 
and bilateral salpingo-oophorectomy (BSO). Frozen section 
histopathological analysis of tissue from the bulging uterine 
mass confirmed a leiomyoma with degeneration. The final 
pathology report showed intravascular leiomyomatosis as-
sociated with multiple intramural and subserosal leiomyomas 
and superficial adenomyosis. Immunohistochemical staining 
Table 3. Comparison of patient characteristics between early and late stage intravenous leiomyomatosis
Patient characteristics Early stage (n=4) Late stage (n=8)
P-value
(2-sided)
Age (median) 45 47 0.927
BMI (average) 23.8 26.2 0.648
Laboratory values 
CA125 21.5 12.7 0.143
Neutrophil lymphocyte ratio 1.51 10.4 0.073
Platelet lymphocyte ratio 0.13 0.23 0.042
Creatinine 0.78 0.65 0.109
Calcium 8.8 8.6 0.648
Phosphate  3.6 3.4 0.927
Gynecological history 
Vaginal delivery 2 (50) 4 (50.0) 0.652
Cesarean section 2 (50) 3 (37.5) 0.652
Intrauterine device usage 2 (50) 1 (12.5) 0.279
Dilation and curettage 4 (100) 6 (75.0) 0.636
Myomectomy 1 (25) 1 (12.5) 0.618
Outcome 
Recurrence or persistent disease 0 (0) 3 (37.5) 0.652
Values are presented as number (%).
BMI, body mass index; CA, cancer antigen.
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results showed positivity for CD31 and CD34 expression. No 
adjuvant therapy was used and no recurrence was found after 
5 years of follow up.
2) Case 2 (stage II, patient #8)
A 49-year-old patient visited our clinic for new infiltration of 
a previously diagnosed myoma on abdomen pelvic CT (APCT). 
Transvaginal ultrasound showed a 7.3×4.6 cm myoma with 
extrinsic compression of both adnexa vessels (Fig. 3). On pel-
vic MRI, a 9.5 cm myoma with IVL along the IVC up to level 
3 lumbar vertebrae was found. PET-CT showed mild flude-
oxyglucose uptake across the entire uterus without uptake 
in IVC thrombus. The patient underwent TAH, BSO, and IVC 
mass removal followed by angioplasty. The final pathology 
report showed IVL of the uterine corpus and IVC. No patho-
logic abnormality was found on either ovaries or fallopian 
tubes. After complete resection, no recurrence was found 
after 6 months follow up, and the patient is still under sur-
veillance. 
3) Case 3 (stage III, patient #9)
A 43-year-old patient visited the emergency department for 
syncope; she was on intravenous heparinization for a known 
intra-cardiac mass. Transvaginal sonography revealed a 4.5 cm 
pedunculated mass within the endometrium, 1 to 2 cm-
sized multiple intramural myomas, and a 4.5 cm ill-defined 
mass around the iliac vessel with suspected retroperitoneal 
penetration (Fig. 4). APCT revealed a tortuous tubular mass 
within the endometrium with extension to the myometrium 
and through the bilateral pelvic vein to the left gonadal, 
renal vein, and IVC. Transthoracic echocardiography (TTE) 
showed an intracardiac mass in the right atrium with dy-
namic movement with cardiac cycle into right ventricle past 
the tricuspid valve. The patient underwent multidisciplinary 
Fig. 2. An example of a stage I, 46-year-old patient with lower abdominal pain. (A) Transvaginal ultrasound showing a conglomeration of 
multiple intramural myomas and (B) pelvic magnetic resonance imaging showing lobulated subserosal myoma with internal hemorrhage 
and dilated pelvic vessels. (C) Specimen obtained from total laparoscopic hysterectomy and bilateral salpingo-oophorectomy.
A                                                   B                                      C
Fig. 3. An example of a stage II, 49-year-old patient with new infiltration of a previously diagnosed myoma on abdomen pelvic computed 
tomography. (A) Transvaginal ultrasound showing a myoma with extrinsic compression of both adnexa vessels and (B) the pelvic magnetic 
resonance imaging showing a 9.5 cm myoma with inferior vena cava (IVC) involvement up to level 3 lumbar vertebra. (C) Specimen ob-
tained from total laparoscopic hysterectomy and bilateral salpingo-oophorectomy, and IVC mass removal. 
A                                                B                                                     C
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surgery with a general surgeon and a cardiothoracic sur-
geon. A TAH with left salpingo-oophorectomy, intravenous 
mass removal through the dissection of the IVC, of both re-
nal veins, the left gonadal and the internal iliac veins, in ad-
dition to removal of an intracardiac mass with extension to 
proximal pulmonary artery were performed under a 2-stage 
operation with complete cardiopulmonary bypass. The final 
pathology report indicated multiple submucosal leiomyo-
mas, a hemorrhagic corpus luteal cyst of left ovary, and IVL 
on the uterine adnexa and the left broad ligament. Tissue 
samples from extrauterine lesions were consistent with IVL. 
After surgery, no remnant intracardiac mass was detected 
on follow up TTE, and an initial finding of mild pulmonary 
hypertension prior to the surgical procedure was normal-
ized. However, on the 1-year follow up using transvaginal 
sonography, a 6.6 cm hypoechoic mass with a 2.6 cm inter-
nal cystic portion was detected on the right adnexa. APCT 
showed a 4.6 cm low attenuating mass in the right iliac 
fossa. The patient underwent right salpingo-oophorectomy 
(RSO), para-ovarian mass excision, and lymph node sam-
pling. Longitudinal opening of the ovarian vessel exposed a 
rubbery, jelly-like material. The patient did not receive any 
adjuvant therapy and was free from disease recurrence on 
APCT after 6 years of follow up. 
4) Case 4 (stage IV, patient #12) 
A 47-year-old patient visited our hospital for heavy men-
strual bleeding and had a history of recurrent myoma. The 
Fig. 4. An example of a stage III, 43-year-old patient presenting with recurrent syncope episode. (A) magnetic resonance imaging show-
ing a 7 cm-sized ‘comma’ shaped thrombosis, extending from the inferior vena cava (IVC) intrahepatic portion to the right atrium. (B) The 
transthoracic echocardiography showing an intracardiac mass with dynamic movement past the tricuspid valve into the right ventricle. (C) 
Specimen from total abdominal hysterectomy, left salpingo-oophorectomy, and IVC and intracardiac mass removal. (D) One-year follow 
up showing localized recurrence at right iliac fossa found on abdomen pelvic computed tomography. (E) Specimen obtained from right 
salpingo-oophorectomy and para-ovarian mass excision.
A                                 B                                     C
D                                                                        E 
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patient underwent previous treatment with a gonadotropin-
releasing hormone (GnRH) agonist for a 10 cm-sized myoma 
and had undergone laparoscopic myomectomy 2 years prior 
to visiting our hospital. On initial evaluation, transvaginal 
ultrasound showed the uterus enlarged to a 20-week ges-
tational size and multiple intramural myomas (11.9 cm on 
the upper segment and 7.3 cm on the lower segment) with 
degeneration and internal necrotic lesion with the absence 
of increased regional blood flow (Fig. 5). The patient un-
derwent total laparoscopic hysterectomy, RSO, left salpin-
gectomy, and mass excision of multiple parasite myomas. 
Intraoperatively, myomas were observed on the uterine wall, 
the large bowel, and the omentum. The final pathology 
report indicated multiple leiomyomas with hydropic de-
generation in the myometrium and omentum. After an un-
eventful one-month follow up, the patient was lost on the 
6-month follow up. After 3 years, the patient presented at 
the emergency department complaining of lower abdominal 
pain and right back pain. Pelvic MRI showed a 12-cm mass 
on the right side of the pelvic cavity and a small nodule in 
both basal lungs. The differential diagnosis included a recur-
rent myoma with benign metastasizing leiomyomatosis and 
sarcoma with lung metastasis. On the second operation, 
a 10×8.0 cm pelvic mass, a 1.0×1.0 cm mass on the left 
infundibulopelvic ligament, and a 0.5×0.5 cm mass on the 
bladder serosa were completely excised. The final pathol-
ogy report indicated leiomyoma with extensive hydropic 
degeneration. After one month, the patient underwent a 
separate video-assisted thoracoscopic surgery operation for 
wedge resection for a total of 8 pulmonary lesions. The final 
pathology report confirmed a BML with the largest dimen-
sion being 1.9 cm. On specific staining, the sample was 
Fig. 5. An example of a stage IV, 47-year-old patient presenting with heavy menstrual bleeding and history of previous myomectomy. Af-
ter 3 years of primary surgery total abdominal hysterectomy, bilateral salpingo-oophorectomy, (A) the abdomen pelvic computed tomogra-
phy showed recurrence with a 12 cm-sized pelvic mass and (B) bilateral lung nodules on chest computed tomography. Specimen obtained 
from (C) pelvic mass excision and (D) video-assisted thoracoscopic surgery guided resection of bilateral basal lung nodule. 
A                                              B
C                                                                   D
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focal positive for ER, PR, and SMA. On 3 months follow up, 
the patient had no evidence of recurrence on APCT, and the 
abnormal chest X-ray finding had resolved.
Discussion 
For the first time to our knowledge, we present a sizable 
case series from a single center in Korea. Analysis of clini-
cal characteristics showed that these patients were mostly 
pre- or peri-menopausal and parous with a history of D&C 
procedures. Aside from patients with IVL extension to distant 
organs who presented with cardiac symptoms, most patients 
presented at the clinic because of symptoms similar to clas-
sical leiomyomas such as heavy menstrual bleeding, increase 
in myoma size, or lower abdominal discomfort. Tumor mark-
ers including CA125 and CA19-9 were not elevated beyond 
normal ranges. The results of the laboratory tests including 
those for creatinine, calcium, and phosphate were similar 
for early stage and late stage IVL. While a trend for high NLR 
in advanced stage IVL was observed, the standard deviation 
among sample values was too large for statistical signifi-
cance. PLR was statistically higher in the late stage IVL group. 
A total of 2 stage II patients and one stage IV patient experi-
enced recurrence on follow up.
As common as leiomyomas are, variants such as IVL and 
BML are considered extremely rare. Indeed, fewer than 200 
cases of IVL have been reported after the first description 
by Birch-Hirschfeld in 1896. However, we gathered a sizable 
case series indicating that taking into consideration IVL and 
BML is important in differential diagnosis of aberrant leio-
myoma, especially when a patient visits the clinic with a large 
myoma or increased size thereof, innumerable small myomas, 
or myomas with abnormal qualitative characteristics such as 
degeneration or internal necrosis. Although the etiology is 
currently unknown, recent molecular cytogenetic studies have 
suggested that IVL cases have a gene expression profile similar 
to that of uterine leiomyoma as well as leiomyosarcoma which 
explains their quasi-malignant behavior [11].
In order to stratify the clinical extent of IVL, we have adopt-
ed the concept of IVL staging proposed by Ma et al. [10]. Pa-
tients with stage I IVL are difficult to distinguish from classical 
leiomyoma based on routine blood tests and transvaginal 
sonography alone. Based on the size of the largest myoma 
on ultrasound, the size and number of myomas in stage I 
IVL are not consistent. A total 2 of 4 patients presented with 
a myoma of less than 5 cm and visited our hospital for ab-
normal uterine bleeding; thus, IVL was incidentally found on 
post-operative pathology. The 2 other patients with stage 
I IVL had huge myomas of 18 cm (patient #1) and 10 cm 
(patient #3) in size, which was in fact larger than the largest 
myoma of all other patients categorized in late stage IVL. The 
average size of the largest myoma in stage II IVL patients was 
8.6 cm and that of stage III and IV IVL patients combined 
was 8.0 cm. In other words, stage I IVL patients were either 
incidentally diagnosed or likely would not have been missed 
due to the huge pelvic mass. Furthermore, no case of recur-
rence was observed in stage I IVL.
On the other end of the spectrum, patients with stage 
III or IV IVL would have been identified, given their cardiac 
symptoms or abnormal findings on chest X-ray. In our study, 
all stage III IVL patients had all distant lesions completely 
resected. Nonetheless, the importance of a multidisciplinary 
approach during the surgical procedure, including general 
surgeons and cardiothoracic surgeons cannot be more em-
phasized, as previous studies report on the challenges associ-
ated with complete resection of advanced stage IVL [12]. In 
the middle ground, the stage II IVL patients could have been 
easily missed on transvaginal ultrasound; APCT and pelvic 
MRI were the most useful diagnostic modality in our study. In 
terms of laboratory studies, subgroup analysis showed that 
NRL and PLR were higher in stage II IVL compared to stage 
I IVL. NLR was 14.6 vs. 1.51 and PLR was 0.25 vs. 0.13 for 
stage II IVL and stage I IVL, respectively. Recently, NLR and 
PLR have been suggested as markers for systemic inflamma-
tion in various solid tumors and non-cancerous conditions 
including endometriosis. In endometrial cancer, pre-operative 
NLR and PLR levels were associated with advanced stage, 
lymph node metastasis, and adverse clinical outcome includ-
ing survival [13]. Similar to malignant conditions, systemic 
inflammation such as relative thrombocytosis, neutrophilia, 
and lymphocytopenia may underlie the acute phase of intra-
venous mass extension in stage II IVL. Overall, these patients 
in stage II IVL represent the cohort who will benefit the most 
from heightened suspicion by individual clinicians, because 
the recurrence rate in stage II IVL was found to be at least 
as high as stage III and IV IVL. The overall recurrence rate of 
25.0% in our study is comparable to the previously reported 
rate, which ranged from 16.6% to 31.0% [14,15]. 
Although IVL and BML were once thought of as distinct en-
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tities, evidence is accumulating on the shared origin of these 
leiomyoma variants with extrauterine manifestation [16,17]. 
It is possible that cases with concurrent IVL and BML have 
been under-reported. Nonetheless, we have also performed 
a separate statistical analysis with the IVL group only to show 
that the trend and pattern of statistical significant is consis-
tent either with or without the inclusion of the BML group. 
Limitations to our study include the retrospective study 
design and the small sample size. A prospective study with 
a larger sample size would have permitted a more sophisti-
cated statistical analysis regarding prognosis and treatment. 
Since the majority of IVL and BML patients are known to be 
pre-menopausal, identification of factors associated with dis-
ease recurrence may help clinicians make decisions regarding 
surgical castration. Young patients subjected to ovary-sparing 
procedures, especially for those who had stained positive for 
ER or PR markers, may have benefited from adjuvant therapy 
using GnRH agonist. The choice of adjuvant therapy was not 
consistent in our patient group. 
IVL and BML are benign myoma variants with a para-
doxically metastatic clinical presentation. Careful inquiry of 
systemic symptoms, the presence of underlying systemic 
inflammation, and a high index of suspicion are required for 
an optimal preoperative diagnosis. Furthermore, a multidis-
ciplinary approach is necessary to improve outcomes from 
surgical resections.
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